학술논문
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial
Document Type
Article
Author
Source
In Bone March 2019 120:137-140
Subject
Language
ISSN
8756-3282